9 results about "Micronazole" patented technology

The present invention relates to the technical field of veterinary medicinal products and specifically to a composition for the treatment of a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01–10):(0.1–20):(0.1–5) and a solvent mixture of water and polyethylene glycol in which the main active ingredients are soluble. The composition has considerable curative effects on fungal infections on the skin surfaces of animals, with low toxicity and minimal irritation.

The application discloses a series of afluconazole derivatives or pharmaceutically acceptable inorganic salts, organic salts and solvates thereof. The application also discloses a preparation method of the afluconazole derivatives and application of the afluconazole derivatives in preparation of medicines for treating or preventing fungal infections. Experimental results show that the preliminary in-vitro antifungal activity of the target compounds is obviously better than that of afluconazole and other currently widely used azole antifungal medicines (such as miconazole, fluconazole and oterconazole), the water solubility of the target compounds is better, the antibacterial spectrum is wider, the activity is higher, the pharmacokinetic properties are better, and the target compounds have further development potential.

The invention establishes a high performance liquid chromatography analysis method for measuring benzoic acid in miconazole nitrate cream, and the method has the advantages of strong specificity, high sensitivity and accuracy, and good repeatability and durability. Chromatographic conditions are as follows: an HPLC (High Performance Liquid Chromatography) system is a simerflight U3000 high performance liquid chromatograph (UV / DAD detector) or similar equipment; a chromatographic column is a chromatographic column taking octadecylsilane chemically bonded silica as a filling agent; the mobile phase consists of A, B and C; wherein A is a phosphate buffer solution, B is acetonitrile, and C is methanol. In addition, the concentration of phosphate in the phosphate buffer solution is 0.05 mol / L, and the pH is adjusted to be 3.5-4.0; the volume ratio of A to B to C is in the range of (40-50): 35: (15-25); the detection wavelength is 230 nm; the sample size is 10 microliters; the column temperature is 30 DEG C; the flow velocity is 1.0 ml / min.

The present invention provides a topical pharmaceutical formulation comprising a combination of miconazole or a pharmaceutically acceptable salt thereof and domiphen bromide, a formulation vehicle and a viscosity modifier; wherein the ratio of w / w% miconazole (salt) to w / w% domiphen bromide is between 6 to 20 endpoints included and wherein the amount of viscosity modifier is sufficient to adjust the viscosity of the topical formulation to a value of 1000-4600 mPa.s measured at 25°C. The invention further provides use of said formulation in a treatment of vaginal Candida (biofilm) infections, wherein once daily use of 4.5-5.5 g of the formulation for a duration of 7 days performed better than a reference product and unexpectedly also performed better than a formulation with a double domiphen bromide dose. Improved performance was the relapse prevention for a duration of at least 28 days in human patients treated for a vulvovaginal Candida (biofilm) infection.

The present invention relates to the technical field of veterinary medicinal products, in particular a composition for the treatment of a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01–10):(0.1–20):(0.1–5) and a mixed solvent of water and dimethylacetamide in which the main active ingredients are soluble. The composition has a significant curative effect on fungal infections on the skin surface of animals, with low toxicity and minimal irritation.

1. Name of the product in this design: Packaging Kit (Miconazole Nitrate Cream). 2. Purpose of this design: for packaging and holding items. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design points: 3D model of Kit 1. 5. Other situations requiring explanation: Kit description: Kit 1 is the outer packaging box, and Kit 2 is the inner packaging tube.

The invention relates to a compound antibacterial spray for pets as well as a preparation method and application of the compound antibacterial spray. Comprising the following preparation raw materials in percentage by mass: 3-7% of chlorhexidine gluconate, 3-8% of miconazole nitrate, 3-8% of ivermectin, 5-10% of glycerol, 2-8% of a carboxymethyl cellulose solution, 12-18% of modified mesoporous silicon, 5-10% of jojoba oil, 0.1-2% of Tween 80, 1-3% of oil-soluble azone, 8-15% of absolute ethyl alcohol and 35-45% of purified water. Wherein the modified mesoporous silicon is obtained after modification of D-cysteine and / or polyethyleneimine. The preparation method comprises the following steps: loading chlorhexidine gluconate, miconazole nitrate, ivermectin, jojoba oil, Tween 80 and oil-soluble azone on modified mesoporous silicon prepared by modifying D-cysteine and / or polyethyleneimine in a multi-layer form, coating with carboxymethyl cellulose, and mixing with absolute ethyl alcohol and purified water to obtain the compound antibacterial spray for pets. The compound antibacterial spray for pets can realize a lasting antibacterial function and is relatively good in storage stability.

Disclosed in the present invention are a series of efinaconazole derivatives or pharmaceutically acceptable inorganic salts, organic salts, solvates, optical isomers or polymorphs thereof. Also disclosed are a preparation method therefor and a use of these efinaconazole derivatives in the preparation of a drug for the treatment or prevention of fungal infection. Experimental results have shown that a plurality of target compounds exhibit significantly better preliminary in vitro antifungal activity than the lead compound efinaconazole and other azole antifungal drugs widely used clinically at present (such as miconazole, fluconazole, and oteseconazole), show relatively good water solubility, a wide antifungal spectrum, high activity, and good pharmacokinetic properties, and have further research and development potential.

The utility model relates to the field of miconazole nitrate processing, in particular to a miconazole nitrate processing device. The miconazole nitrate processing device provided by the utility model has the beneficial effects that in the miconazole nitrate processing and producing process, a worker can conveniently control the grinding degree of grinding miconazole nitrate raw materials into powder. According to the technical scheme, the miconazole nitrate processing device comprises a material placing base and sliding rods fixedly connected to the left side and the right side of the upper portion of the material placing base, a lifting frame is connected to the two sliding rods in a sliding mode, a rotating rod is rotationally connected to the middle of the lifting frame, a supporting plate is fixedly connected to the bottom of the rotating rod, and the supporting plate is fixedly connected to the supporting plate. The bottom of the supporting plate is fixedly connected with a transverse rod, the left side and the right side of the transverse rod are each rotationally connected with a grinding wheel, the front side and the rear side of the bottom of the material containing base are each fixedly connected with a supporting frame, and grinding discs are placed on the two supporting frames.